Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

HTG Molecular Diagnostics, Inc. (HTGM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5638-0.0264 (-4.47%)
At close: 04:00PM EDT
0.5500 -0.01 (-2.45%)
After hours: 04:31PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close0.5902
Open0.6160
Bid0.5400 x 3000
Ask0.6000 x 900
Day's Range0.5284 - 0.6180
52 Week Range0.4600 - 6.3300
Volume112,716
Avg. Volume1,055,556
Market Cap6.229M
Beta (5Y Monthly)1.29
PE Ratio (TTM)N/A
EPS (TTM)-2.5300
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for HTGM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • HTG Molecular Diagnostics, Inc.
    Analyst Report: Agilent Technologies, Inc.Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
    Rating
    Fair Value
    Economic Moat
    yesterdayMorningstar
View more
  • GlobeNewswire

    HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference

    TUCSON, Ariz., Sept. 26, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that management will participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference at the Lotte New York Palace in New York City on Wednesday, September 28, 2022. John Lubniewski, HTG CEO will be a participant in the panel discussion, “Predictive

  • Zacks

    HTG Molecular Diagnostics, Inc. (HTGM) Moves to Buy: Rationale Behind the Upgrade

    HTG Molecular Diagnostics, Inc. (HTGM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • GlobeNewswire

    The Fundación Instituto Valenciano de Oncología Leverages HTG Technology for Breast Cancer Laboratory-Developed Test

    TUCSON, Ariz., Sept. 20, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that the Fundación Instituto Valenciano de Oncología, located in Valencia, Spain (IVO), with its partners, the Fundación Pública Andaluza Progreso y Salud (FPS) and the Centro de Investigación Biomédica en Red (CIBER), have developed a laboratory-developed test (LDT) (t

Advertisement
Advertisement